MA52032A - Régulateurs de nrf2 - Google Patents
Régulateurs de nrf2Info
- Publication number
- MA52032A MA52032A MA052032A MA52032A MA52032A MA 52032 A MA52032 A MA 52032A MA 052032 A MA052032 A MA 052032A MA 52032 A MA52032 A MA 52032A MA 52032 A MA52032 A MA 52032A
- Authority
- MA
- Morocco
- Prior art keywords
- nrf2 regulators
- nrf2
- regulators
- Prior art date
Links
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 title 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175505P | 2015-06-15 | 2015-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52032A true MA52032A (fr) | 2021-01-20 |
Family
ID=56178402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052032A MA52032A (fr) | 2015-06-15 | 2016-06-15 | Régulateurs de nrf2 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10272095B2 (fr) |
| EP (2) | EP3766878B1 (fr) |
| JP (1) | JP6786527B2 (fr) |
| KR (1) | KR20180018684A (fr) |
| CN (1) | CN108137557B (fr) |
| AU (1) | AU2016280236B2 (fr) |
| CA (1) | CA2988374A1 (fr) |
| ES (2) | ES2834490T3 (fr) |
| MA (1) | MA52032A (fr) |
| RU (1) | RU2018101080A (fr) |
| WO (1) | WO2016203401A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2988338C (fr) | 2015-06-15 | 2024-05-14 | Glaxosmithkline Intellectual Property Development Limited | Regulateurs de nrf2 |
| CN108137557B (zh) | 2015-06-15 | 2021-09-07 | 葛兰素史密斯克莱知识产权发展有限公司 | Nrf2调节剂 |
| WO2017060854A1 (fr) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles utilisés comme régulateurs de nrf2 |
| WO2017060855A1 (fr) * | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Pyrazoles d'arylcyclohéxyle utilisés en tant que régulateurs de nrf2 |
| WO2018104766A1 (fr) * | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | Dérivés d'acide propanoïque 3-(2,3-dihydro-1h-inden-5-yl) et leur utilisation en tant que régulateurs de nrf2 |
| AU2017376900A1 (en) * | 2016-12-15 | 2019-05-23 | Glaxosmithkline Intellectual Property Development Limited | NRF2 compounds |
| JP2020097526A (ja) * | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3624885B1 (fr) | 2017-05-19 | 2026-02-18 | Trudell Medical International Inc. | Dispositif à pression expiratoire positive |
| WO2019116231A1 (fr) | 2017-12-11 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Activateur de nrf2 pour le traitement d'une lésion pulmonaire aiguë, d'un syndrome de détresse respiratoire aiguë et d'un syndrome de dysfonction d'organes multiples |
| USD903097S1 (en) | 2018-05-18 | 2020-11-24 | Trudell Medical International | Mask |
| USD874064S1 (en) | 2018-05-18 | 2020-01-28 | Trudell Medical International | Mask |
| US11643407B2 (en) * | 2018-05-23 | 2023-05-09 | Glaxosmithkline Intellectual Property Development Limited | Indanes as NRF2 activators |
| USD893806S1 (en) | 2018-11-09 | 2020-08-18 | Trudell Medical Internationl | Mask and shroud |
| CA3121952C (fr) | 2018-12-05 | 2025-05-13 | Scohia Pharma, Inc. | Composé macrocyclique et son utilisation |
| CN113474349B (zh) | 2019-02-15 | 2024-03-01 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为nrf2活化剂的羟基吡啶并氧氮杂环庚三烯 |
| BR112021023927A2 (pt) | 2019-05-31 | 2022-02-08 | Ube Industries | Composto, e, composição farmacêutica |
| CN113519459B (zh) * | 2021-06-11 | 2022-03-25 | 中国科学院合肥物质科学研究院 | 一种采用调节肝细胞ros水平的磁场发生装置在调节人/鼠肝细胞氧化应激中的应用 |
| WO2023210741A1 (fr) | 2022-04-28 | 2023-11-02 | 第一三共株式会社 | Composé benzotriazole |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB348944A (en) * | 1930-07-05 | 1931-05-21 | Ig Farbenindustrie Ag | Improvements in the concentration of aqueous formic acid |
| CY1308A (en) | 1979-12-06 | 1985-12-06 | Glaxo Group Ltd | Device for dispensing medicaments |
| ATE23272T1 (de) | 1981-07-08 | 1986-11-15 | Draco Ab | Pulverinhalator. |
| ES286422Y (es) | 1982-10-08 | 1986-09-16 | Glaxo Group Limited | Dispositivo para administrar medicamentos a pacientes |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
| PT83094B (pt) | 1985-07-30 | 1993-07-30 | Glaxo Group Ltd | Dispositivos proprios para a administracao de medicamentos a pacientes |
| SK280968B6 (sk) | 1990-03-02 | 2000-10-09 | Glaxo Group Limited | Balenie medikamentu na použite v inhalačnom prístroji |
| US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| IL99537A (en) | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical compositions containing them |
| US5217994A (en) | 1991-08-09 | 1993-06-08 | Merck & Co., Inc. | Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives |
| WO1993012075A1 (fr) | 1991-12-10 | 1993-06-24 | Shionogi & Co., Ltd. | Derive d'acide hydroxamique a base de sulfonamide aromatique |
| JPH10501222A (ja) | 1994-05-27 | 1998-02-03 | メルク エンド カンパニー インコーポレーテッド | 破骨細胞仲介骨吸収を抑制するための化合物 |
| GB9700226D0 (en) | 1997-01-08 | 1997-02-26 | Glaxo Group Ltd | Inhalation device |
| TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| EP1360173A2 (fr) | 2001-01-25 | 2003-11-12 | Guilford Pharmaceuticals Inc. | Composes de liaison de la cyclophiline carboxylique trisubstituee et leur utilisation |
| JPWO2002080899A1 (ja) | 2001-03-30 | 2005-01-06 | エーザイ株式会社 | 消化器疾患治療剤 |
| TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
| CN110894196A (zh) | 2001-09-21 | 2020-03-20 | 百时美-施贵宝控股爱尔兰无限公司 | 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂 |
| TWI320039B (en) | 2001-09-21 | 2010-02-01 | Lactam-containing compounds and derivatives thereof as factor xa inhibitors | |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| US20040157919A1 (en) | 2002-01-25 | 2004-08-12 | Yong-Qian Wu | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| WO2004007464A1 (fr) | 2002-07-10 | 2004-01-22 | Sumitomo Pharmaceuticals Co., Ltd. | Derive d'imidazole |
| US7589116B2 (en) | 2003-04-03 | 2009-09-15 | Merck & Co. Inc. | Biaryl substituted pyrazoles as sodium channel blockers |
| WO2006044133A1 (fr) | 2004-09-24 | 2006-04-27 | Axys Pharmaceuticals, Inc. | Inhibiteurs de la tryptase, contenant de la cetone active |
| WO2006118320A1 (fr) | 2005-04-28 | 2006-11-09 | Takeda Pharmaceutical Company Limited | Composé de thiénopyrimidone |
| GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
| AR058289A1 (es) | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | Colector para ser usado en dispensador de medicamento |
| WO2008002490A2 (fr) | 2006-06-23 | 2008-01-03 | Radius Health, Inc. | Traitement de symptômes vasomoteurs par des modulateurs des récepteurs d'œstrogène sélectifs |
| CN101939053A (zh) | 2007-09-06 | 2011-01-05 | 默沙东公司 | 可溶性的鸟苷酸环化酶活化剂 |
| WO2010005922A1 (fr) | 2008-07-07 | 2010-01-14 | Fasgen, Inc. | Nouveaux composés, compositions pharmaceutiques les contenant, et leurs procédés d'utilisation et de préparation |
| CN102264916B (zh) | 2008-07-25 | 2014-08-20 | 英福康姆株式会社 | 新的癌基因nrf2 |
| EP2401265B1 (fr) | 2009-02-26 | 2016-09-14 | Merck Sharp & Dohme Corp. | Derives d'acide 1-pyri(mid)in-2-yl-pyrazole-4-carboxylique utiles dans la therapie ou la prophylaxie de maladies cardiovasculaires |
| WO2011094890A1 (fr) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Dérivés phénylalanines et leur utilisation comme modulateurs non peptidiques du récepteur de glp-1 |
| WO2012068589A2 (fr) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| WO2013067036A1 (fr) * | 2011-10-31 | 2013-05-10 | Rutgers, The State University Of New Jersey | Inhibiteurs directs de l'interaction keap1-nrf2 en tant que modulateurs de l'inflammation par anti-oxydant |
| EP2816023A4 (fr) | 2012-02-13 | 2015-09-09 | Takeda Pharmaceutical | Composé à noyaux aromatiques |
| WO2013155528A2 (fr) | 2012-04-13 | 2013-10-17 | Fasgen, Inc. | Méthodes de réduction de l'inflammation cérébrale, de renforcement de la sensibilité à l'insuline et de réduction des taux de céramides |
| US20160046616A1 (en) * | 2013-03-15 | 2016-02-18 | The Johns Hopkins University | Nrf2 small molecule inhibitors for cancer therapy |
| AU2014369153B2 (en) * | 2013-12-18 | 2017-09-21 | Astex Therapeutics Limited | Nrf2 regulators |
| WO2015135091A1 (fr) | 2014-03-10 | 2015-09-17 | Merck Sharp & Dohme Corp. | Dérivés de pipérazine utilisés en tant qu'inhibiteurs de la protéase du vih |
| WO2015138220A1 (fr) | 2014-03-10 | 2015-09-17 | Merck Sharp & Dohme Corp. | Dérivés de pipérazine utilisés en tant qu'inhibiteurs de la protéase du vih |
| CN108137557B (zh) | 2015-06-15 | 2021-09-07 | 葛兰素史密斯克莱知识产权发展有限公司 | Nrf2调节剂 |
| CA2988338C (fr) | 2015-06-15 | 2024-05-14 | Glaxosmithkline Intellectual Property Development Limited | Regulateurs de nrf2 |
| JP2018517732A (ja) | 2015-06-15 | 2018-07-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２レギュレーター |
| WO2017060854A1 (fr) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles utilisés comme régulateurs de nrf2 |
| WO2017060855A1 (fr) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Pyrazoles d'arylcyclohéxyle utilisés en tant que régulateurs de nrf2 |
| WO2018104766A1 (fr) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | Dérivés d'acide propanoïque 3-(2,3-dihydro-1h-inden-5-yl) et leur utilisation en tant que régulateurs de nrf2 |
| ES2901617T3 (es) | 2016-12-14 | 2022-03-23 | Glaxosmithkline Ip Dev Ltd | Bisarilamidas como reguladores de NRF2 |
| JP2020502129A (ja) | 2016-12-14 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２アクチベーターとしての３−オキソ−１，４−ジアゼピニル化合物 |
| US11117905B2 (en) | 2016-12-14 | 2021-09-14 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl heterocycles as NRF2 activators |
-
2016
- 2016-06-15 CN CN201680047401.XA patent/CN108137557B/zh active Active
- 2016-06-15 ES ES16731340T patent/ES2834490T3/es active Active
- 2016-06-15 CA CA2988374A patent/CA2988374A1/fr not_active Abandoned
- 2016-06-15 KR KR1020187000829A patent/KR20180018684A/ko not_active Withdrawn
- 2016-06-15 RU RU2018101080A patent/RU2018101080A/ru not_active Application Discontinuation
- 2016-06-15 US US15/735,977 patent/US10272095B2/en active Active
- 2016-06-15 MA MA052032A patent/MA52032A/fr unknown
- 2016-06-15 AU AU2016280236A patent/AU2016280236B2/en not_active Ceased
- 2016-06-15 EP EP20192327.3A patent/EP3766878B1/fr active Active
- 2016-06-15 JP JP2017564883A patent/JP6786527B2/ja active Active
- 2016-06-15 EP EP16731340.2A patent/EP3307729B1/fr active Active
- 2016-06-15 WO PCT/IB2016/053545 patent/WO2016203401A1/fr not_active Ceased
- 2016-06-15 ES ES20192327T patent/ES2910938T3/es active Active
-
2019
- 2019-04-04 US US16/375,047 patent/US10485806B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2988374A1 (fr) | 2016-12-22 |
| ES2834490T3 (es) | 2021-06-17 |
| US20190224212A1 (en) | 2019-07-25 |
| CN108137557B (zh) | 2021-09-07 |
| RU2018101080A3 (fr) | 2019-07-17 |
| US10485806B2 (en) | 2019-11-26 |
| JP6786527B2 (ja) | 2020-11-18 |
| ES2910938T3 (es) | 2022-05-17 |
| US10272095B2 (en) | 2019-04-30 |
| AU2016280236B2 (en) | 2019-02-07 |
| CN108137557A (zh) | 2018-06-08 |
| EP3766878A1 (fr) | 2021-01-20 |
| EP3307729A1 (fr) | 2018-04-18 |
| WO2016203401A1 (fr) | 2016-12-22 |
| US20180169110A1 (en) | 2018-06-21 |
| JP2018517730A (ja) | 2018-07-05 |
| EP3307729B1 (fr) | 2020-09-02 |
| RU2018101080A (ru) | 2019-07-15 |
| HK1256199A1 (zh) | 2019-09-13 |
| AU2016280236A1 (en) | 2017-12-21 |
| KR20180018684A (ko) | 2018-02-21 |
| BR112017027137A2 (pt) | 2018-08-14 |
| EP3766878B1 (fr) | 2022-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2025024I1 (no) | Elranatamab | |
| FIC20240042I1 (fi) | siltakabtageeniautoleuseeli | |
| NO2024008I1 (no) | Pirtobrutinib | |
| NO2023007I1 (no) | Vutrisiran | |
| MA52309A (fr) | Régulateurs de nrf2 | |
| MA52032A (fr) | Régulateurs de nrf2 | |
| EP3381654A4 (fr) | Procédé de moulage par soufflage de liquide | |
| DK3292136T3 (da) | Penicillin-g-acylaser | |
| DE112015006486A5 (de) | Inkubationsrinne | |
| EP3390373C0 (fr) | Synthèse de la dota | |
| DE102015206660A8 (de) | Plattenaufteilanlage | |
| EP3308871A4 (fr) | Dispositif de sertissage | |
| DE112015005906A5 (de) | Gurtschlossbringer | |
| ES1138645Y (es) | Pieza enroscada | |
| MA42035A (fr) | 2-thiopyrimidinones | |
| EP3381902A4 (fr) | Tétrafluorosulfanylpyridine | |
| DE102015000551A8 (de) | Rotationszerstäuberturbine | |
| DE112016001124A5 (de) | Spannschutz | |
| DE102015226549B8 (de) | Hybridheizmodul | |
| UA32883S (uk) | Пензель-макловиця | |
| CU20150012S4 (es) | Tenaza de soldar | |
| NO20151704A1 (no) | Skvettern | |
| FI11104U1 (fi) | Kairauskone | |
| DK3365601T3 (da) | Krematorier | |
| ES1145809Y (es) | Mini -jamonero |